SV Life Sciences Fund IV (GP), L.P., 10% Owner at KalVista Pharmaceuticals, Inc. (KALV), sold 245,908 shares at $29.70 ($7.1M) on 2019-03-26, disclosed to the SEC on 2019-03-28.
Open-market sale of $7.1M KALV by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.70 | 831 | $25K | 0.3% |
| 2 | $29.70 | 29,262 | $869K | 12.3% |
| 3 | $29.70 | 29,262 | $869K | 12.3% |
| 4 | $29.06 | 1,599 | $46K | 0.7% |
| 5 | $29.06 | 56,318 | $1.6M | 23.1% |
| 6 | $29.06 | 56,318 |
| $1.6M |
| 23.1% |
| 7 | $27.80 | 1,012 | $28K | 0.4% |
| 8 | $27.80 | 35,653 | $991K | 14.0% |
| 9 | $27.80 | 35,653 | $991K | 14.0% |
| Total | $28.84 avg | 245,908 | $7.1M | 100% |
| Filing → |
| NGSX | SELL | 2010-05-05 | $3.1M | — | Filing → |